Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 2 3Phase EARLY_PHASE1 1

Status

Completed 3

Sponsor Class

NETWORK 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Breast 1

Conditions

Endometrial Adenocarcinoma 1Breast Neoplasms 1Advanced, Persistent, or Recurrent Endometrial Cancer 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Has results × Medroxyprogesterone Acetate × Clear all
NCT02228681 2024-09-19

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

GOG Foundation

Phase 2 Completed
74 enrolled 13 charts
Gynecologic

Advanced, Persistent, or Recurrent Endometrial Cancer

NCT00577122 2023-10-16

Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer

Indiana University

Phase 2 Completed
30 enrolled 13 charts
Breast

Breast Neoplasms

NCT00064025 2016-04-11

Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

GOG Foundation

Phase 2 Completed
75 enrolled 6 charts
Gynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡